PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 2020Journal for ImmunoTherapy of Cancer152 citationsOpen Access

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

LXLu XieJXJie XuXSXin Sun

Key Points

Key points are not available for this paper at this time.

Abstract

Nct03359018.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xie et al. (2020) studied this question.

synapsesocial.com/papers/69dab51b00ab073a27838f6ahttps://doi.org/10.1136/jitc-2020-000798
Ask AI
Helpful
Bookmark
Share
View Full Paper